IP Library Granted Patent US 9,186,273
Granted Patent B2
US 9,186,273 · App. 12/773,239 · Granted Nov 17, 2015

Methods of treating pains associated with neuroma, nerve entrapment, and other conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,186,273
App. No.
12/773,239
Granted
Nov 17, 2015
Kind
B2
Abstract

The present disclosure is drawn to methods for treating various types of pain. Specifically, a method for treating various types of pain includes the application of an analgesic system to a skin surface of a subject experiencing the pain and maintaining the analgesic system on the skin surface for a period of time of at least 30 minutes. The analgesic system applied to the skin surface can include a heating component and a local anesthetic formulation which includes at least one local anesthetic. The heating component can be capable of heating the skin surface to a temperature of 36° C. to 42° C.

Claims (26)

1. A method for treating connective tissue pain, comprising:

a) applying an integrated analgesic system to a skin surface of a subject experiencing connective tissue pain, said analgesic system, comprising:

i) a heating device configured to heat the skin surface to a temperature of 35° C. to 47° C., and

ii) a local anesthetic formulation including a eutectic mixture of lidocaine and tetracaine, wherein the local anesthetic formulation is applied to the skin surface over the existing pain;

b) heating the skin surface to a temperature of 35° C. to 47° C.; and

c) maintaining the analgesic system on the skin surface for a period of time of at least 2 hours.

2. The method of claim 1 , wherein the heating device begins heating at about the same time as the analgesic system is applied to the skin surface.

3. The method of claim 1 , wherein the weight percentage of the eutectic mixture is at least 30 wt % of the local anesthetic formulation.

4. The method of claim 1 , wherein the local anesthetic formulation has a skin contact region having an area of 2 cm 2 to 200 cm 2 .

5. The method of claim 1 , wherein the local anesthetic formulation has a skin contact region having an area of 7 cm 2 to 150 cm 2 .

6. The method of claim 1 , wherein the local anesthetic formulation has a skin contact region, said skin contact region having an area of 8 cm 2 to 15 cm 2 .

7. The method of claim 1 , wherein the connective tissue pain is ligament pain.

8. The method of claim 1 , wherein the connective tissue pain is tendon pain.

9. The method of claim 1 , wherein the connective tissue pain is iliotibial band pain.

10. The method of claim 1 , wherein the connective tissue pain is associated with a blood vessel.

11. The method of claim 8 , wherein the connective tissue pain is caused by tendinopathy.

12. The method of claim 11 , wherein the tendinopathy is clavicular or patellar tendonitis.

13. The method of claim 11 , wherein the tendinopathy is tennis elbow.

14. The method of claim 11 , wherein the tendinopathy is medial tibial stress syndrome.

15. The method of claim 1 , wherein the heating device is configured to generate heat by an exothermic oxidative chemical reaction.

16. The method of claim 1 , wherein the skin surface is heated to a temperature of 36° C. to 42° C.

17. The method of claim 1 , wherein the skin surface is heated to a temperature of 38° C. to 42° C.

18. The method of claim 1 , wherein the skin surface is heated to a temperature of 36° C. to 40° C.

19. The method of claim 1 , further comprising removing the analgesic system after the period of at least two hours, wherein after removal of the analgesic system, the subject experiences relief of the connective tissue pain for a period of at least 4 hours.

20. The method of claim 1 , further comprising removing the analgesic system after the period of at least two hours, wherein after removal of the analgesic system, the subject experiences relief of the connective tissue pain for a period of at least 6 hours.

21. The method of claim 1 , further comprising removing the analgesic system after the period of at least two hours, wherein after removal of the analgesic system, the subject experiences relief of the connective tissue pain for a period of at least 12 hours.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded May 17, 2023
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 063695/0543 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2023
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS AGENT
To: NUVO PHARMACEUTICALS INC.; ARALEZ PHARMACEUTICALS CANADA INC.; NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY (F/K/A NUVO PHARMACEUTICALS (IRELAND) LIMITED)
Reel/Frame 062974/0236 →
SECURITY INTEREST Recorded Dec 31, 2018
From: NUVO PHARMACEUTICALS INC.; NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY; ARALEZ PHARMACEUTICALS CANADA INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS AGENT
Reel/Frame 047875/0410 →
CHANGE OF NAME Recorded Dec 1, 2016
From: NUVO RESEARCH INC.
To: NUVO PHARMACEUTICALS INC.
Reel/Frame 040792/0150 →
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2015
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 034664/0991 →
GENERAL SECURITY AGREEMENT Recorded Aug 20, 2012
From: NUVO RESEARCH INC.
To: PALADIN LABS INC.
Reel/Frame 028816/0225 →
CONFIRMATION OF ASSIGNMENT Recorded Jul 10, 2012
From: NUVO RESEARCH AMERICA, INC.
To: NUVO RESEARCH INC.
Reel/Frame 028535/0690 →
CONFIRMATION OF ASSIGNMENT Recorded Jul 6, 2012
From: ZARS PHARMA, INC.
To: NUVO RESEARCH AMERICA, INC.
Reel/Frame 028509/0561 →